These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 20538597)
21. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330 [TBL] [Abstract][Full Text] [Related]
22. Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models. Upadhyay M; Agarwal S; Bhadauriya P; Ganesh S Neurobiol Dis; 2017 Apr; 100():39-51. PubMed ID: 28063983 [TBL] [Abstract][Full Text] [Related]
23. Lafora disease: Current biology and therapeutic approaches. Mitra S; Gumusgoz E; Minassian BA Rev Neurol (Paris); 2022 Apr; 178(4):315-325. PubMed ID: 34301405 [TBL] [Abstract][Full Text] [Related]
24. Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity. DePaoli-Roach AA; Segvich DM; Meyer CM; Rahimi Y; Worby CA; Gentry MS; Roach PJ Hum Mol Genet; 2012 Apr; 21(7):1604-10. PubMed ID: 22186021 [TBL] [Abstract][Full Text] [Related]
25. Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway. Upadhyay M; Gupta S; Bhadauriya P; Ganesh S Biochem Biophys Res Commun; 2015 Aug; 464(1):106-11. PubMed ID: 26102034 [TBL] [Abstract][Full Text] [Related]
26. P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease. Kumarasinghe L; Garcia-Gimeno MA; Ramirez J; Mayor U; Zugaza JL; Sanz P Neurobiol Dis; 2023 Feb; 177():105998. PubMed ID: 36638890 [TBL] [Abstract][Full Text] [Related]
27. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Gentry MS; Worby CA; Dixon JE Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8501-6. PubMed ID: 15930137 [TBL] [Abstract][Full Text] [Related]
28. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion. Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631 [TBL] [Abstract][Full Text] [Related]
29. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Solaz-Fuster MC; Gimeno-Alcañiz JV; Ros S; Fernandez-Sanchez ME; Garcia-Fojeda B; Criado Garcia O; Vilchez D; Dominguez J; Garcia-Rocha M; Sanchez-Piris M; Aguado C; Knecht E; Serratosa J; Guinovart JJ; Sanz P; Rodriguez de Córdoba S Hum Mol Genet; 2008 Mar; 17(5):667-78. PubMed ID: 18029386 [TBL] [Abstract][Full Text] [Related]
30. Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex. Rubio-Villena C; Garcia-Gimeno MA; Sanz P Int J Biochem Cell Biol; 2013 Jul; 45(7):1479-88. PubMed ID: 23624058 [TBL] [Abstract][Full Text] [Related]
31. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration. Spuch C; Ortolano S; Navarro C Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717 [TBL] [Abstract][Full Text] [Related]
32. Glycogen phosphomonoester distribution in mouse models of the progressive myoclonic epilepsy, Lafora disease. DePaoli-Roach AA; Contreras CJ; Segvich DM; Heiss C; Ishihara M; Azadi P; Roach PJ J Biol Chem; 2015 Jan; 290(2):841-50. PubMed ID: 25416783 [TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan. Sullivan MA; Nitschke S; Steup M; Minassian BA; Nitschke F Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800070 [TBL] [Abstract][Full Text] [Related]
34. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons. Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741 [TBL] [Abstract][Full Text] [Related]
35. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease. Rai A; Mishra R; Ganesh S Hum Mol Genet; 2017 Dec; 26(24):4778-4785. PubMed ID: 28973665 [TBL] [Abstract][Full Text] [Related]
37. Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease? Puri R; Ganesh S Autophagy; 2010 Nov; 6(8):1229-31. PubMed ID: 20818153 [TBL] [Abstract][Full Text] [Related]
38. Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice. Zafra-Puerta L; Colpaert M; Iglesias-Cabeza N; Burgos DF; Sánchez-Martín G; Gentry MS; Sánchez MP; Serratosa JM Epilepsy Res; 2024 Feb; 200():107317. PubMed ID: 38341935 [TBL] [Abstract][Full Text] [Related]
39. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). Worby CA; Gentry MS; Dixon JE J Biol Chem; 2008 Feb; 283(7):4069-76. PubMed ID: 18070875 [TBL] [Abstract][Full Text] [Related]
40. Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice. Irimia JM; Tagliabracci VS; Meyer CM; Segvich DM; DePaoli-Roach AA; Roach PJ J Biol Chem; 2015 Sep; 290(37):22686-98. PubMed ID: 26216881 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]